Rationale Memories can return to a labile state and become amenable to modification by pharmacological and behavioral manipulations after retrieval. This process may reduce the impact of aversive memories and provide a promising therapeutic technique for the treatment of anxiety disorders. A growing body of evidence suggests that the mammalian neuropeptide oxytocin (OT) plays a role in the regulation of emotional memories in animals. However, the effects of OT on threat memory in humans remain largely unknown. Objectives This study aimed to investigate the effects of OT administration following threat memory retrieval on subsequent memory expression in human participants. Methods In a double-blind, randomized, placebo-controlled, between-subject design, 61 healthy human individuals completed a 3-day experiment. All the participants underwent threat conditioning on day 1. On day 2, the participants were randomized to receive an intranasal dose of OT (40 IU) or placebo after memory retrieval, or an intranasal dose of OT (40 IU) without retrieval. On day 3, the participants were tested for extinction and reinstatement. Results On day 3, all groups showed equivalent stimulus discrimination during the early phase of extinction. However, the group that received OT following a memory reminder showed a greater decline in stimulus discrimination by the late phase of extinction relative to the two other groups. Conclusions The results indicate that OT did not block reconsolidation to prevent the return of threat memory but rather interacted with post-retrieval processes to facilitate next day extinction. The study provides novel preliminary evidence for the role of OT in human threat memory.
In anxiety disorders, maladaptive threat memories are prevalent, and treatments have focused on coping with them. Until recently, it was thought that memories are relatively stable after memory consolidation, a process that occurs during a short window immediately after learning. However, recent findings demonstrate that memories can again become vulnerable to pharmacological or behavioral interference during a consolidation-like phase called reconsolidation, which may occur when a memory is retrieved (Nader et al. 2000; Agren 2014 ; Lee et al. 2017) . The ability to disrupt the reconsolidation of threat memory provides a promising approach to alleviate the maladaptive effects of threat memories in anxiety disorders.
A promising pharmacological candidate for therapeutic interventions regulating threat memory is oxytocin (OT). OT is a mammalian neuropeptide synthesized in the paraventricular and supraoptic nuclei of the hypothalamus and centrally This article belongs to a Special Issue on Psychopharmacology of Extinction.
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00213-018-5074-6) contains supplementary material, which is available to authorized users. released within these regions as well as limbic sites, such as the hippocampus and amygdala (Neumann 2007; Campbell 2008) . The OT receptor is abundantly expressed in the medial prefrontal cortex (mPFC) and the central and basolateral nuclei of the amygdala (Maroun and Wagner 2016) . These regions are known for their role in regulating defensive responses and threat memory.
Evidence in rodents indicates that OT enhancement attenuates anxiety-like behaviors (Sabihi et al. 2014) . The specific effects of OT on threat conditioning and extinction, however, have been somewhat complex. On the one hand, enhancing OT neurotransmission using central administration of OT in rodents prior to threat conditioning decreased threat expression and facilitated extinction. When administrating prior to extinction training, OT impaired threat extinction (Toth et al. 2012) . A subsequent rodent study showed that OT can act both to reduce as well as enhance threat responses, depending on the timing and neural circuit location of OT manipulation. For example, direct application of OT into the mPFC infralimbic region (IL-mPFC) after threat memory retrieval facilitated extinction training on the next two consecutive days, whereas OT enhancement in the amygdala resulted in impaired extinction (Lahoud and Maroun 2013) . Systemic administration of OT in rodents after threat memory retrieval reduced freezing 24 h later, indicating reconsolidation blockade (Hou et al. 2015) .
In healthy human participants, OT treatment following threat conditioning and prior to immediate extinction training facilitated extinction with increased activation of the prefrontal cortex and amygdala inhibition (Eckstein et al. 2015) , as well as enhanced extinction recall 24 h later (Acheson et al. 2013) . However, administration of OT prior to exposure therapy for arachnophobia hindered treatment response (Acheson et al. 2015) . Thus, despite the growing body of research implicating OT as a promising candidate for targeting threat memory, extant evidence yields a complex pattern of results, pointing to interactions particularly with the timing and mode of learning.
To further clarify OT's ability to modify threat memories, we examined administration of OT immediately following threat memory reactivation and examined effects on subsequent threat memory retrieval and extinction in healthy humans. Specifically, we report a double-blind, placebo-controlled, between-subject design study aimed at investigating the effect of intranasal OT on threat memory reconsolidation in 61 healthy humans. We use a 3-day threat conditioning, reactivation, and extinction procedure, which has been widely used to assess various drug effects on reconsolidation across species (for review, see Kroes et al. 2016) . We hypothesized that post-retrieval OT would block reconsolidation and prevent the return of threat memory. Given the mixed evidence, however, another possibility is that post-retrieval OT would facilitate extinction.
Methods and materials

Participants
The study was approved by and conducted in accordance with regulations of the Ethics committee of South China Normal University. Seventy-nine healthy participants were recruited from South China Normal University via flyers and Internet advertisements (see Table 1 for demographics). Seventy-nine participants were screened over the phone and upon arrival at the laboratory to assure they did not meet criteria for current or past psychiatric disorders; were not taking any medicine and having no allergies to specific medications; and did not have a current or recent diagnosis of substance abuse or dependence, history of cardiac illness, seizure disorder, brain injury, neurologic disorder, color blindness, or history of head injury with loss of consciousness for more than 3 min. Since endogenous OT levels can fluctuate across the menstrual cycle, female participants who were pregnant, in menstrual period, or currently using hormonal contraceptives during the follicular phase of the menstrual cycle (i.e., up to 10 days following onset of menstruation) would be excluded. Five subjects were excluded due to equipment malfunction or had nonmeasurable skin conductance response (SCR) to the shock (< 0.02). Thirteen subjects were removed from the study due to the failed acquisition (mean CS− > CS+ in late acquisition). Therefore, 61 subjects were included in final analysis. All participants provided written informed consent and were financially compensated for their participation.
Assignment to treatment group
On day 2, the participants were assigned to the reminder + OT group, reminder + placebo group, and no reminder + OT group. The participants were randomly assigned into these three groups, with only one constraint ensuring equal gender distribution across the groups. This procedure allows for evaluation of treatment effects without potential confounds from between-group differences in strength of initial conditioning.
Treatment
The OT Nasal Spray was purchased from Sichuan Meike Pharmaceutical Co., Ltd., China. This polypeptide drug is a colorless transparent liquid. The participants selfadministered OT (reminder + OT group and no reminder + OT group) or placebo (reminder + placebo group) intranasally by applying five 0.1-ml puffs per nostril (40 international units of OT in total) after a reminder (one nonreinforced CS+ presentation) or no reminder. This dose has been shown to increase the sensitivity of emotional recognition in healthy humans and produce no side effects (Leknes et al. 2013; MacDonald et al. 2011) . The placebo spray consisted of normal saline and was administered in an identical fashion. To blind the drug treatment, OT or saline was placed in plain white bottles identified by a number between 1 and 9. Each participant was assigned a number, which was then used by another experimenter unaware of the correspondence between the numbers and content. The identity of drug treatment was unblinded after completion of data collection.
Apparatus
Computer tasks A Lenovo desktop computer, 22-in monitor, and headphones were used to present the visual stimuli and the video (played during the waiting period after the drug/placebo administration) to the participants. The software E-Prime 2.0 was used to program and present experimental procedures while integrating the SCRs and mild electric shocks with the threat conditioning and extinction computer tasks. We employed images of two cylinders with different colors (purple, blue) that served as CS+ and CS−. Assignment of colors to stimuli was counterbalanced across participants, and the images were identical in size and resolution.
SCR measurements SCR was measured using shielded AgAgCl electrodes, filled with standard NaCl electrolyte gel and attached to the middle phalanges of the second and third fingers of the non-dominant hand. The electrode cables were grounded through an RF filter panel. The skin conductance signal was amplified and recorded with a BIOPAC MP36 Systems skin conductance module connected to a computer. Data were continuously recorded at a rate of 200 samples per second. An off-line analysis of the analog skin conductance waveforms was conducted with AcqKnowledge software (BIOPAC Systems).
Delivery of mild non-painful electric shocks The unconditioned stimulus (US) was a mild electric shock with duration of 200 ms, delivered to the wrist using a Digitimer DG2A Constant Voltage Stimulator (Digitimer Ltd.). The stimulating bar electrode was attached to the participant's wrist with medical tape. Before acquisition, shock intensity levels were set manually for each individual by delivering gradually more intense shocks (with a maximum of 60 V) until the subject reported that the shock level was unpleasant but not painful.
Procedure
The experiment was conducted over three consecutive days at approximately the same time each day. There were three experimental stages: threat conditioning on day 1, reactivation and/or drug/placebo administration on day 2, and extinction and reinstatement tests on day 3. The procedures and timeline for these three phases are depicted in Fig. 1 .
The participants were initially screened by a telephone interview. On day 1, they were asked to fill out the Symptoms Checklist 90 (SCL-90) and the State-Trait Anxiety Inventory (STAI-S and STAI-T) prior to the experiment. Then, SCR and electric shocks were tested in order to verify equipment and measurement integrity. During acquisition, the CS+ was paired with the US in a partial reinforcement schedule (43% of presentation), and the CS− was never paired with a shock. SCR was measured continuously.
On day 2, reactivation and drug administration were conducted. The participants were randomly assigned into the three experimental groups; in the reminder + OT group and the reminder + placebo group, the participants were connected to the SCR and shock electrodes as described for threat acquisition on day 1, and presented with one unreinforced CS+ (the reminder). OT or placebo administration immediately followed reactivation. The participants in the no reminder + OT group self-administered the OT in the waiting area without the reminder. Then, all the participants watched a neutral (planet travel guides for Uranus and Neptune) video for 60 min after drug administration. Before leaving, the participants were given a side effects checklist and asked to fill it out and bring it back on day 3.
On day 3, the participants were asked to rate their shock expectancy before the experiment by asking, BHow much do you expect to receive a shock today?^; they were instructed to choose their option from B1 (unlikely)^to B5 (very likely)^. Then, the extinction and reinstatement tests were conducted. All the participants returned to the lab and were fitted with the SCR and shock electrodes as described for threat acquisition on day 1. In order to measure the return of conditioned defensive responses, the participants saw eight presentations of each OT oxytocin, PLC placebo, SD standard deviation, BMI body mass index stimulus type (CS+, CS−) in a random order without the US. Reinstatement immediately followed, during which the participants received four unsignaled mild electric shocks (without stimuli presentation) to reinstate remaining conditioned defensive responses. This was followed by a re-extinction session where the participants again saw non-reinforced presentations of the CS+ and CS− (eight trials each). SCR was measured continuously.
Data analysis
Demographic and questionnaire data were analyzed by using one-way ANOVA; follow-up t tests were used to assess specific differences. Analysis of SCR was conducted on the responses during each session, broken down into blocks of two trials each (Fig. S1 ). Repeated-measures ANOVA was used to examine the overall effects of stimulus, block and treatment group, and any interactions between the factors. Follow-up t tests were used to assess specific differences. Analyses were conducted using SPSS version 18 (IBM, Armonk, NY) and alpha was set at P < 0.05.
Results
Demographics
There were no significant gender, age, and BMI differences between treatment groups (Table 1) . In initial analyses, gender was entered as a factor, and BMI and age as covariates, and were then dropped from the models as none had a significant effect.
Questionnaires
No group differences were found between groups on STAI-S, STAI-T, SCL-90, or subscales of SCL-90 (Table 2) . Analysis of shock expectancy prior to the experimental session on day 3 (Table 2 ) using one-way ANOVA showed significant group difference (F(2,58) = 3.84, P < 0.05); follow-up t tests confirmed significantly higher shock expectancy in the no reminder + OT group compared to the reminder + OT group (t(38) = − 2.69, P < 0.05) and the reminder + PLC group (t(37) = 2.17, P < 0.05).
Learned defensive responses
Day 1-conditioned threat acquisition
To assure equivalent and significant acquisition across the randomly assigned groups (Fig. 2) , we conducted ANOVA with factors of group (reminder + OT, reminder + PLC, no reminder + OT) × block (1, 2, 3, 4) × stimulus (CS+, CS−). There was no evidence for group differences as indicated by the nonsignificant main effect of group (F(2,58) = 2.21, P > 0.05, partial η 2 = 0.07), group × block interaction (F(6,174) = 1.48, P > 0.05, partial η 2 = 0.05), group × stimulus interaction (F(2,58) = 0.80, P > 0.05, partial η 2 = 0.03), or group × block × stimulus interaction (F(6,174) = 1.17, P > 0.05, partial η 2 = 0.04). SCR responses were higher to the CS+ compared to the CS−, and this differential responding increased from early blocks to late blocks as indicated by a main effect of block (F(3,174) = 22.77, P < 0.001, partial η 2 = 0.28) and stimulus (F(1,58) = 59.53, P < 0.001, partial η 2 = 0.51), and also a block × stimulus interaction (F(3,174) = 12.70, P < 0.001, partial η 2 = 0.18). Follow-up t tests confirmed significantly higher responding to the CS+ vs. CS− in all groups during the last two blocks of acquisition (block 3: reminder + OT group, P < 0.01; reminder + placebo group, P < 0.01; no reminder + OT group, P < 0.001; block 4: reminder + OT group, P < 0.001; reminder + placebo group, P < 0.001; no reminder + OT group, P < 0.001). These results confirm sufficient and similar acquisition across all groups.
Day 2-threat memory reactivation
Independent-sample t tests confirmed similar reactivation between the reminder + OT and reminder + placebo groups (t(41) = 1.36, P > 0.05).
Day 3-threat extinction
To assess the overall effect of post-retrieval OT administration on next day extinction (Fig. 3) , we examined conditioned Fig. 1 Schematic depiction of the experimental design defensive responses to the stimuli during the four blocks of extinction. Repeated-measures ANOVA was conducted with between-subject factor of group (three treatment groups) and within-subject factors of block (1, 2, 3, 4) and stimulus (CS+, CS−), which yielded a significant three-way interaction (F(6,174) = 2.22, P < 0.05, partial η 2 = 0.07). Follow-up t tests indicated that threat memory recovery was evident in all groups: all groups showed significant stimulus discrimination at the first block of extinction (reminder + OT group, t(21) = 4.06, P < 0.01; reminder + placebo group, t(20) = 2.31, P < 0.05; no reminder + OT group, t(17) = 2.24, P < 0.05). However, only the reminder + OT group showed no evidence for stimulus discrimination at the last block of extinction (reminder + OT group, t(21) = 0.05, P > 0.05; reminder + placebo group, t(20) = 2.76, P < 0.05; no reminder + OT group, t(17) = 3.35, P < 0.01). These results indicate that postretrieval administration of OT facilitates extinction after 24 h, whereas other treatments rendered the conditioned threat memory less amenable to attenuation.
The effect of post-reactivation OT administration on extinction may be exhibited not only by lack of stimulus discrimination by the end of the extinction session but also by a significant reduction in discrimination (CS+ minus CS−) from the early to the late phase of extinction (Fig. 4) . To assess the degree of reduction in stimulus discrimination during the four blocks of extinction, we conducted paired-sample t tests to compare stimulus discrimination between blocks during extinction for each group. The analysis confirmed that only the reminder + OT group showed significant and gradual reduction in stimulus discrimination from early to late blocks: the discrimination in block 1 was significantly higher than in block 3 (t(21) = 3.15, P < 0.01) and block 4 (t(21) = 3.48, P < 0.01). Furthermore, discrimination in block 2 was significantly higher than in block 3 (t(21) = 2.58, P < 0.05) and block 4 (t(21) = 2.97, P < 0.01). The no reminder + OT group maintained similar stimulus discrimination across all blocks on extinction (all P's > 0.05), and despite the reduction from block 1 to block 3 (t(20) = 2.25, P < 0.05), the reminder + placebo group maintained significant discrimination during the last block of extinction (Fig. 3, middle panel) . Finally, we calculated a threat extinction index (stimulus discrimination in the first minus the last block), which was the highest in the reminder + OT group (Fig. 5) and significantly larger than the no reminder + OT group (t(38) = 2.58, P < 0.05). These results further indicate that post-retrieval OT administration facilitated extinction training.
Day 3-threat reinstatement
Following the extinction session on day 3, the participants were exposed to four unsignaled shocks followed by a reextinction session (reinstatement, Fig. 6 ). Repeated-measures ANOVA with between-subject factor of group (three treatment groups) and within-subject factors of block (1, 2, 3, 4) and stimulus (CS+, CS−) yielded no significant effect (F(6,174) = 1.711, P = 0.121). Reinstatement effects following extinction are typically weak and limited to the first few trials (e.g., Kindt et al. 2009; Homan et al. 2017; Hu et al. 2018) .
Nevertheless, further exploratory analysis using pairedsample t tests revealed that the reminder + OT group, who did not show stimulus discrimination in late extinction blocks, continued to exhibit no evidence of stimulus discrimination through all blocks of re-extinction (all P's > 0.05). However, both reminder + placebo and no reminder + OT groups showed significant stimulus discrimination in the second block of reinstatement (t(20) = 2.93, P < 0.01, t(17) = 2.30, P < 0.05, respectively). One-way ANOVA confirmed both were significantly higher than stimulus discrimination during the respective second Fig. 3 Stimulus discrimination during threat extinction. Means with 95% confidence intervals in each group during four blocks of extinction. Confidence intervals that do not cross the vertical dashed line at zero indicate that the corresponding contrast is different from zero and thus statistically significant. A significant three-way interaction of group × block × stimulus and follow-up t tests confirmed memory recovery in all groups at the beginning of day 3 extinction (24 h after drug administration), but only the group that had post-retrieval administration of OT showed successful and adequate extinction by the end of the extinction session Fig. 4 The reduction in stimulus discrimination from block 1 to block 4 during extinction. Paired-sample t tests confirmed significant and gradual reduction of stimulus discrimination (CS+ minus CS−) in the reminder + OT group (R + OT), but not in the reminder + placebo group (R + PLC) or the no reminder + OT group (NR + OT). One asterisk, P < 0.05; two asterisks, P < 0.01. Error bars represent standard errors Fig. 5 Threat extinction index by treatment group. Independent-sample t tests confirmed a significantly higher extinction index (stimulus discrimination in the first minus the last block of extinction) in the reminder + OT group (R + OT) compared to the no reminder + OT group (NR + OT). Asterisk, P < 0.05. Error bars represent standard errors block of the reminder + OT group (F(2,58) = 3.43, P < 0.05, partial η 2 = 0.11).
Discussion
The present study reports the first examination of the effects of post-retrieval administration of OT on the expression of threat memory in healthy human individuals. In contrast to some findings in rodents (Hou et al. 2015) but consistent with others (Lahoud and Maroun 2013) , the current results indicate that post-retrieval administration of OT did not block reconsolidation but rather facilitated extinction the next day, compared to post-retrieval administration of placebo or administration of OT without reactivation. Furthermore, we found that the post-retrieval OT group continued to exhibit lack of stimulus discrimination throughout reinstatement relative to the other two groups, consistent with studies showing that if extinction learning were less effective, defensive reactions should recover during this phase (Vervliet et al. 2013) . These results are consistent with evidence in animals and humans showing that administration of OT facilitates extinction (Toth et al. 2012; Acheson et al. 2013; Lahoud and Maroun 2013; Eckstein et al. 2015) .
There is evidence to suggest that OT could get into the brain via the intranasal route across species. For example, intranasal administration of a high dose of OT (10 μg) in mice activated Fos expression at the paraventricular nucleus, the area postrema, and the dorsal motor nucleus of the vagus (Maejima et al. 2015) . In macaques, 48 IU OT (~10 μg/kg body weight) administered intranasally either with a spray or with a nebulizer induced CSF OT level increase from~35 to~90 pg/mL after 40 min (Dal Monte et al. 2014) . A study in humans (Striepens et al. 2013 ) using combined blood and cerebrospinal fluid (CSF) sampling in subjects receiving either 24 IU of OT (n = 11) or placebo (n = 4) has shown that OT levels significantly increased in both plasma and CSF. Specifically, OT plasma concentrations peaked at 15 min after intranasal administration and decreased after 75 min, and CSF concentrations took up to 75 min to reach a significant level. These findings indicate that intranasally administered OT increases concentrations of the peptide in the brain as well as blood across species, including humans.
Within the threat learning field, a human neuroimaging study showed that when OT (24 IU) was administered intranasally after threat conditioning in humans, prefrontal cortex fMRI signals to conditioned threat increased in the early phase of extinction and evoked an unspecific inhibition of amygdalar response throughout extinction (Eckstein et al. 2015) . In line with this result, rodent studies showed that injection of OT into IL-mPFC following threat memory retrieval facilitated extinction (Lahoud and Maroun 2013) . OT promotes threat extinction by inducing long-lasting LTP of excitatory postsynaptic currents in IL-mPFC brain slices (Ninan 2011) , indicating that OT increases activity-dependent strengthening of glutamatergic synapses in the IL-mPFC. As previous studies have demonstrated that potentiation of synaptic transmission in the IL-mPFC underlies extinction memory (Vouimba and Maroun 2011; Burgos-Robles et al. 2007; Herry and Garcia 2002) , the OT-mediated facilitation of LTP in the IL-mPFC might serve as the neural basis of its extinction-enhancing effect.
The present findings are inconsistent with a recent rodent study showing that post-retrieval OT blocked reconsolidation (Hou et al. 2015) . A possible explanation of the discrepancy might relate to differences in the dose and timing of OT administration. The effects of OT on anxiety and memory in animals are dose-dependent and time-dependent (Peters Fig. 6 Stimulus discrimination in reinstatement. Means with 95% confidence intervals in each group of four blocks of reinstatement. Confidence intervals that do not cross the vertical dashed line at zero indicate that the corresponding contrast is different from zero and thus statistically significant. One-way ANOVA and paired-sample t tests confirmed that both the reminder + placebo group (R + PLC) and the no reminder + OT group (NR + OT) showed significant stimulus discrimination in the second block of reinstatement, and they are both significantly higher than the reminder + OT group (R + OT) Chini et al. 2014 ). In the current study, we have only tested a single dose of intranasal OT in a single time point. Nevertheless, the fact that the extinction facilitation was observed only when OT was preceded by a memory reminder and did not act when administered on its own suggests that at least a partial interaction with reconsolidation processes occurred to modify the memory, rendering it more susceptible to extinction. OT therefore remains a possible candidate for blocking reconsolidation, but further studies are needed to fully assess this effect, which may require a higher dose and repeated use.
Our observation that OT administration after retrieval facilitated the extinction of a consolidated threat memory may explain some controversial findings of OT effects on exposure therapy in clinical populations. A study that investigated OT facilitation of exposure therapy for social phobia failed to show an impact on symptoms (Guastella et al. 2009 ). Another recent study examining arachnophobia patients also indicated that administration of intranasal OT prior to exposure therapy impeded responses as measured by self-report questionnaires (Acheson et al. 2015) . These results are inconsistent with previous evidence from healthy humans demonstrating a facilitating effect of OT on extinction (Acheson et al. 2013; Eckstein et al. 2015) . These latter results were obtained by conducting threat acquisition and extinction on the same day before threat acquisition was consolidated into long-term memory. By contrast, the aversive memories of clinically anxious patients are typically old and well consolidated. Moreover, spider phobia and other real-life memories in anxiety patients may at least in part reflect an innate fear as opposed to an entirely learned threat response acquired through associative learning. These characteristics of age, strength, and quality of memory may influence susceptibility to OT manipulations, at least in certain doses and mode of administration.
Lastly, since explicit measures of expectancy might interact with implicit physiological measurements (Warren et al. 2014) , we focused on assessing physiological threat responses and not subjective fear; future studies could specifically assess the cognitive impact of OT on subjective fear memory.
In summary, we found that OT did not block reconsolidation to prevent the return of threat memory but rather interacted with post-retrieval processes to facilitate next day extinction. The study provides novel preliminary evidence for the role of OT in human threat memory. The results suggest that OT may be used as an adjunctive treatment to exposurebased therapy by administering it following memory retrieval to facilitate subsequent exposure sessions.
